Title : Medical innovations in addiction relapse prevention: Emerging neurobiologic and psychedelic-assisted therapies
Abstract:
Substance use disorders remain a global public health challenge, with relapse rates frequently exceeding 50–70% depending on substance type and comorbid psychiatric conditions. Despite established interventions such as medication-assisted treatment, behavioral therapy, and peer recovery models, long-term durability of remission remains limited. Increasing evidence suggests that addiction relapse is not solely a behavioral phenomenon but reflects underlying neurobiologic dysregulation involving reward circuitry, stress-response systems, trauma-related conditioning, and impaired cognitive flexibility.
This presentation examines emerging medical innovations in addiction relapse prevention with particular focus on psychedelic-assisted therapies, including psilocybin. Recent randomized clinical trials published in high-impact journals have demonstrated promising outcomes in alcohol use disorder, nicotine dependence, and major depressive disorder. The conditions strongly associated with relapse vulnerability. In controlled therapeutic settings, limited administrations of psilocybin combined with structured psychotherapy have produced sustained reductions in heavy drinking days, high smoking abstinence rates, and durable mood improvement.
Proposed mechanisms of action include modulation of the 5-HT2A receptor system, increased neural network connectivity, enhanced neuroplasticity, disruption of maladaptive default mode network activity, and facilitation of emotionally corrective or meaning-centered experiences. These mechanisms may allow patients to interrupt entrenched behavioral patterns and trauma-linked relapse cycles in ways not achieved by conventional pharmacotherapies alone.
Safety considerations, screening protocols, therapeutic structure (preparation, monitored administration, and integration), and evolving regulatory frameworks will be reviewed. The presentation will also discuss how emerging therapies may complement existing evidence-based treatments within multidisciplinary models of care.
By reframing relapse prevention through a neurobiologic and trauma-informed lens, healthcare professionals can better understand the limitations of current approaches and evaluate emerging therapies with scientific rigor. This session aims to provide clinicians and researchers with a balanced, evidence-based overview of innovations that may shape the future of addiction treatment while emphasizing patient safety, ethical practice, and interdisciplinary collaboration.
